Novel Vaccine Delivery Systems Market Thumbnail Image

2021

Novel Vaccine Delivery Systems Market

Novel Vaccine Delivery Systems Market Size, Share, Competitive Landscape and Trend Analysis Report by Delivery Mode, Device : Global Opportunity Analysis and Industry Forecast, 2021-2030.

LS : Pharmaceuticals

Select an option
Author's: Sushant Terdale | Roshan Deshmukh
Publish Date:

Get Sample to Email

Novel Vaccine Delivery Systems Market Overview:

The global novel vaccine delivery systems market size was valued at $5,030 million in 2020 and is projected to reach $14,437 million by 2030 registering a CAGR of 10.8% from 2021 to 2030.

Vaccines, often known as immunizations, are injections that induce the body to generate antibodies or immunity against a disease. Vaccinations are essentially administered to people of different age groups, which strengthen their immune system throughout lifetime and offers protection against different types of infectious diseases. A vaccine generally consists of a disease-causing germ-like agent made from weakened or killed microorganisms, their toxins, or one of their surface proteins. The agent causes the body's immune system to recognize and destroy the agent as a threat. Novel vaccine delivery includes formulations, technologies, methods, and systems to transfer an active pharmaceutical ingredient in the body, as desired, in order to safely accomplish its therapeutic effect. 

Novel-Vaccine-Delivery-System-Market-2021-2030

The growing immunization programs for various diseases such as polio, smallpox, COVID, and hepatitis among others, and their increasing coverage is the key factor that drives the growth of the global novel vaccine delivery system market. In addition, increasing government support for healthcare infrastructure improvements and robust R&D initiatives to produce vaccine with enhanced therapeutic potential and reduced side effects further boost the growth of the market. Moreover, investment of government for immunization programs and development of novel vaccines using various novel approaches further drive the market growth. High cost and unaffordability of safety syringes, as well as the availability of other drug administration methods may hamper the growth of the novel vaccine delivery system market. In contrast, rise in need for safety syringes in emerging economies and FDA approval for the COVID-19 vaccine created lucrative opportunities for the novel vaccine delivery system.

The outbreak of COVID-19 has disrupted workflows in the health care sector across the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of health care. However, there has also been a positive effect and surge in demand for various medical services, including novel vaccine delivery products such as syringe, needle free injection system. Medical disposables such as syringes and needles are a key to corona vaccine delivery, the pandemic is expected to have a positive impact on growth of the smart syringe market in the coming months. In addition, several contracts and tenders are announced by governments for manufacturing and providing syringes on a nationwide scale. For instance, in August 2020, Hindustan Syringes & Medical Devices Ltd. (HMD), confirmed that it has received an order of 140 million auto disable syringes for COVID-19 from the United Nations Children's Fund (UNICEF). Similarly, in July 2020, Retractable Technologies Inc. entered into Technology Investment Agreement (TIA) of $53.6 million with the U.S. government for expanding its domestic production of needles and syringes.

Novel Vaccine Delivery Systems Market Segmentation  

The global novel vaccine delivery systems market is segmented into delivery mode, device and region. On the basis of delivery mode, the market is categorized into intradermal, subcutaneous, intramuscular, and other. By device, it is classified into syringe, needle-free injection system, and others. Syringe again classified into conventional syringe and smart syringe. Smart syringe again segmented into active safety syringes, passive safety syringes, and auto disable syringes. Needle-free injection system again classified into spring-based injector systems, gas propelled/air forced injector system, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Segment Review

Based on delivery mode, the market is segmented into intradermal, subcutaneous, intramuscular, and other. The intramuscular segment dominates the global market in 2020 and is anticipated to continue this trend during the forecast period. The factor which drives the growth of this segment includes, intramuscular vaccine delivery mode are widely adopted as they deliver medications deep into the muscle tissues, which absorbs the medication quickly.

Novel Vaccine Delivery Systems Market
By Delivery Mode
Your browser does not support the canvas element.

Intramuscular segment holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.

On the basis of device, the market is segmented into syringe, needle-free injection system, and others. Needle-free injection system again classified into spring-based injector systems, gas propelled/air forced injector system, and others. Syringe again classified into conventional syringe and smart syringe. Smart syringe again segmented into active safety syringes, passive safety syringes, and auto disable syringes.

The syringe segment is expected to account for the largest revenue during forecast period, owing to cost effectiveness of syringes and they are used in routine immunization and mass vaccination programs.

Novel Vaccine Delivery Systems Market
By Device
Your browser does not support the canvas element.

Syringe segment is projected as one of the most lucrative segment.

Snapshot of the Asia-Pacific Novel Vaccine Delivery Systems Market  

Asia-Pacific is expected to exhibit the fastest market growth during the forecast period, owing to constantly expanding healthcare infrastructure, economic development, are projected to drive the growth of the novel vaccine delivery systems market in emerging countries in Asia-Pacific. In addition, Asia-Pacific is the most populous region across the globe. Increase in population is further anticipated to proliferate increased consumption of vaccines, which ultimately drives the novel vaccine delivery systems market growth. Moreover, growing immunization programs and their increasing coverage also boost the market growth of novel vaccine delivery system market. According to National Health System, the Government of India's Universal Immunization Program provides immunization against seven vaccine-preventable diseases: Diphtheria, Pertussis, Tetanus, Polio, Measles, severe form of Childhood Tuberculosis, Hepatitis B, Hiaemophilus influenza type b (Hib) and Diarrhea. In addition, according to UNICEF India 2020, over 9 million immunization sessions are held across India every year toward full immunization coverage. The Program introduced new vaccines, including the Pneumococcal Conjugate Vaccine (PCV) and Rotavirus Vaccine (RVV). 

The key market players profiled in the report include Altaris Capital Partners, LLC (Kindeva Drug Delivery), Becton, Dickinson, and Company, Carl Zeiss Foundation (Schott AG), Gerresheimer AG, Gurnet Point Capital (Corium International Inc.), Inovio Pharmaceuticals, Inc. (Bioject Medical Technologies), PharmaJet, Inc., Retractable Technologies, Inc., Terumo Corporation, and VAXXAS Pty Ltd.

Novel Vaccine Delivery Systems Market
By Region
2030
North America 
Europe
Asia-Pacific
LAMEA

North America is expected to experience growth at the highest rate, registering a CAGR of 9.8 % during the forecast period.

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the global novel vaccine delivery systems market along with the current trends and future estimations to explain the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the novel vaccine delivery systems market growth is provided in the report.
  • Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing novel vaccine delivery systems market opportunities.
  • Extensive analysis of the key segments of the industry helps to understand the application and products of novel vaccine delivery systems used across the globe.
  • Key market players and their strategies have been analyzed to understand the competitive outlook of the novel vaccine delivery systems market.

Key Market Segments

By Delivery Mode

  • Intradermal 
  • Subcutaneous
  • Intramuscular 
  • Other

By Device

  • Syringe
    • Conventional Syringe
    • Smart Syringe
      • Active Safety Syringes
      • Passive Safety Syringes
      • Auto Disable Syringes
  • Needle free injection System
    • Spring-based Injector Systems
    • Gas Propelled/Air Forced Injector Systems
    • Others
  • Others 

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China 
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Novel Vaccine Delivery Systems Market Report Highlights

Aspects Details
icon_5
By DELIVERY MODE
  • Intradermal
  • Subcutaneous
  • Intramuscular
  • Others
icon_6
By DEVICE
  • Syringe
    • General Syringe
    • Smart Syringe
      • Active Safety Syringes
      • Passive Safety Syringes
      • Auto Disable Syringes
  • Needle-free Injection System
    • Spring-based Injector Systems
    • Gas Propelled/Air Forced Injector Systems
    • Others
  • Others
icon_7
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Russia, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Thailand, Malaysia, Indonesia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, UAE, Argentina, Rest of LAMEA)
icon_8
Key Market Players

INOVIO PHARMACEUTICALS, INC. (BIOJECT MEDICAL TECHNOLOGIES), CARL ZEISS FOUNDATION (SCHOTT AG), GERRESHEIMER AG, BECTON, DICKINSON, AND COMPANY, RETRACTABLE TECHNOLOGIES, INC., GURNET POINT CAPITAL (CORIUM INTERNATIONAL INC.), TERUMO CORPORATION, VAXXAS PTY LTD, CAPITAL PARTNERS, LLC (KINDEVA DRUG DELIVERY), PHARMAJET, INC.

Analyst Review

Vaccine is a suspension containing weakened or destroyed microbes or toxins, as well as antibodies and lymphocytes that are given to prevent sickness. Vaccines stimulate the immune system to combat certain pathogens. Formulations, technologies, methods, and systems for transferring an active pharmaceutical component throughout the body as required in order to safely achieve its therapeutic effect are all included in novel vaccine delivery.

Growing immunization programs & their increasing coverage, increasing government support and investment, development of novel vaccines, are expected to drive the growth of the novel vaccine delivery system. Furthermore, rise in need for safety syringes in emerging economies and FDA approval to COVID 19 Vaccine also create a lucrative opportunity for market growth. However, high cost and unaffordability of safety syringes, alternative modes of drug delivery are expected to hinder the growth of the market. 

North America is expected to remain dominant during the forecast period. The rising incidence of a number of chronic illnesses and disorders, such as polio, measles, and influenza, is driving demand for vaccination and contributes toward growth of the novel vaccine delivery system in this region. Moreover, Asia-Pacific is expected to offer lucrative opportunities to the key players during the forecast period. The market growth in this region is attributable to the large patient pool, increase in healthcare awareness, rise in healthcare expenditure, growth in disposable income, and rise in government spending.

Author Name(s) : Sushant Terdale | Roshan Deshmukh
Frequently Asked Questions?

The total market value of Novel Vaccine Delivery Systems market is $5,029.6 million in 2020.

The forcast period for Novel Vaccine Delivery Systems market is 2021 to 2030

The market value of Novel Vaccine Delivery Systems market in 2021 is $5,738.8 million.

The base year is 2020 in Novel Vaccine Delivery Systems market

Top companies such as 3M Company, Becton Dickinson & Company, Bioject Medical Technologies, Inc. (Inovio Pharmaceutical Inc.), Corium International, Inc., Gerresheimer AG, Medtronic plc., PharmaJet, SCHOTT AG, Retractable Technologies, Inc., and Vaxxas. held a high market position in 2020.

Syringe segment is the most influencing segment owing to cost effectiveness of syringes and they are used in routine immunization and mass vaccination programs. Moreover, syringes are the most common device used in vaccine delivery.

Growing immunization programs & their increasing coverage, increasing government support for various immunization programs and investment for R & D to develop new vaccines drive the growth of market.In addition, rise in need for safety syringes in emerging economies and FDA approval to COVID-19 Vaccine create lucrative opportunities for the novel vaccine delivery system.

Asia-Pacific is expected to experience the highest growth rate during the forecast period, owing tolarge patient pool, increase in healthcare awareness, rise in healthcare expenditure, growth in disposable income, and rise in government spending.

The term "novel vaccine delivery" refers to formulations, technologies, procedures, and systems that are used to safely deliver an active medicinal component into the body.

Novel Vaccine Delivery Systems products are used to safely deliver an active medicinal component into the body.

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Novel Vaccine Delivery Systems Market

Global Opportunity Analysis and Industry Forecast, 2021-2030.